The Conversation (0)
Sensus Healthcare, Inc. Announces Completion of Initial Public Offering, including Underwriters' Exercise of Over-Allotment Option in Full
Jun. 08, 2016 08:07AM PST
Medical Device Investing
Northland Securities, Inc., and Neidiger, Tucker, Bruner, Inc. acted as joint book-running managers for the offering. A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on June 2, 2016. The final prospectus related to the offering may be obtained from Northland Securities by mail at 750 Third Ave, …
Northland Securities, Inc., and Neidiger, Tucker, Bruner, Inc. acted as joint book-running managers for the offering.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on June 2, 2016. The final prospectus related to the offering may be obtained from Northland Securities by mail at 750 Third Ave, Suite 2401, New York, NY 10017, by calling: (800) 851-2920, or by email: ahammer@northlandcapitalmarkets.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Sensus
Sensus Healthcare, Inc. is a medical device company that is committed to enabling non-invasive and cost-effective treatment of non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy x-ray radiation technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development activities. Sensus has successfully incorporated the SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, the SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For more information, visit https://www.sensushealthcare.com.
Investor Relations:
Jeffrey Goldberger / Allison Soss
KCSA Strategic Communications
Phone: 212-896-1249 / 212-896-1267
Email: jgoldberger@kcsa.com / asoss@kcsa.com
To view the original version on PR Newswire, visit:https://www.prnewswire.com/news-releases/sensus-healthcare-inc-announces-completion-of-initial-public-offering-including-underwriters-exercise-of-over-allotment-option-in-full-300281645.html
SOURCE Sensus Healthcare
Related Links
https://www.sensushealthcare.com